ArticleInternational journal of cardiology. Heart & vasculature2025
Clinical burden and management gaps in atherosclerotic cardiovascular disease: A nationwide study of 687,212 patients in Taiwan, 2017-2023.
Article in International journal of cardiology. Heart & vasculature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Highlights recently published in the International Journal of Cardiology Heart & Vasculature on sex differences in susceptibility, manifestation and outcome of cardiovascular diseases.International journal of cardiology. Heart & vasculature · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This nationwide study aimed to analyze temporal trends in hospitalized atherosclerotic cardiovascular disease (ASCVD) incidence, evaluate lipid testing patterns and goal attainment rates, and assess healthcare utilization among ASCVD patients in Taiwan. Methods: Using Taiwan's National Health Insurance database linked with laboratory data (2017-2023), we identified patients with incident hospitalized ASCVD. We calculated age-standardized incidence rates and analyzed lipid-lowering therapy patterns, low-density lipoprotein cholesterol (LDL-C) testing, and healthcare utilizations during index hospitalization and one-year follow-up. Results: Among 687,212 patients with incident ASCVD, age-standardized incidence decreased by 10% (from 256.3 to 231.8 per 100,000 person-years) from 2017 to 2023, with marked sex disparities (male-to-female ratio: 1.73). Concerning increases in incidence were observed among adults aged 20-29 (12.6%) and 70-79 (19.0%). Among all subtypes of ASCVD, ischemic heart disease (IHD) showed the highest adjusted incidence (99.86 per 100,000 person-years). LDL-C testing rates were suboptimal during index hospitalization (64.8%), with significant variation across ASCVD subtypes (highest in stroke: 80.2% and lowest in peripheral artery disease: 39.2%). Only 34.1% achieved LDL-C <70 mg/dL at one year post-discharge. Lipid-lowering therapy initiation was low during hospitalization (48.9%), peaked at 3 months (60.9%), then stabilized at 57%. Within one year post-discharge, 40.8% had emergency department visits, 40.6% were rehospitalized, and one-year mortality rate reached 13.2%. Conclusion: Our findings reveal substantial gaps in ASCVD care and lipid management in Taiwan's healthcare system, highlighting critical opportunities for improving preventive strategies and optimizing cardiovascular outcomes in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.